 <h1>Onasemnogene abeparvovec Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to onasemnogene abeparvovec: intravenous suspension</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Suspension)</p><p>Acute Serious Liver Injury: Acute serious liver injury and elevated aminotransferases can occur with onasemnogene abeparvovec-xioi. Patients with pre-existing liver impairment may be at higher risk. Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer systemic corticosteroid to all patients before and after onasemnogene abeparvovec-xioi infusion. Continue to monitor liver function for at least 3 months after infusion.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, onasemnogene abeparvovec may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking onasemnogene abeparvovec:</p><p>
<i>More common</i>
</p><ul>
<li>Clay-colored stools</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>fever</li>
<li>headache</li>
<li>itching, skin rash</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>stomach pain or tenderness</li>
<li>swelling of the feet or lower legs</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back pain</li>
<li>blurred vision</li>
<li>confusion</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>drowsiness</li>
<li>seizures</li>
<li>sweating</li>
</ul><p>
<!-- end intravenous suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to onasemnogene abeparvovec: intravenous kit</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included elevated aminotransferases and vomiting.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>During clinical trials, transient decreases in platelet counts, some meeting the criteria for thrombocytopenia, have been reported.</p><p><b>Frequency not reported</b>: Thrombocytopenia, transient decreases in platelet count</p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory insufficiency<sup>[Ref]</sup></p><p>One patient presented with respiratory insufficiency 12 days after receiving this drug.  The patient was found to have respiratory syncytial virus (RSV) and parainfluenza in respiratory secretions; episodes of hypotension were followed by seizures.  Approximately 30 days following the infusion, leukoencephalopathy was found and the patient died after withdrawal of life support, 52 days after this drug was infused.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Elevated cardiac troponin-I levels<sup>[Ref]</sup></p><p>Elevated cardiac troponin-I levels up to 0.176 mcg/L have been observed following infusion.  The clinical importance of this finding is unknown; however, cardiac toxicity has been observed in animal studies.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Vomiting</p><h3>Hepatic</h3><p>Elevated aminotransferases (ALT and/or AST) to greater than the upper limit of normal (ULN) occurred in 12 of 44 patients in clinical trials.  Two patients had AST and ALT elevations of up to 48 x ULN; these patients were otherwise asymptomatic with normal total bilirubin.  Following corticosteroid management, these abnormalities resolved.  One patient with preexisting transaminase elevations (who received this drug with the recommended corticosteroid regimen) became jaundiced about 7 weeks after the infusion.  Laboratory testing showed an AST level approximately 80 x ULN and ALT level approximately 45 x ULN.  Liver biopsy showed acute massive degeneration of hepatocytes, and massive mixed inflammatory infiltrate (primarily CD8-positive T-lymphocytes).  Following treatment with corticosteroids, the patient recovered to baseline.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated aminotransferases (27.3%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Zolgensma (10.1-10.5 kg) (onasemnogene abeparvovec)." AveXis, Bannockburn, IL. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about onasemnogene abeparvovec</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Onasemnogene abeparvovec-xioi Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Zolgensma</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Spinal Muscular Atrophy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to onasemnogene abeparvovec: intravenous kit</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included elevated aminotransferases and vomiting.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>During clinical trials, transient decreases in platelet counts, some meeting the criteria for thrombocytopenia, have been reported.</p><p><b>Frequency not reported</b>: Thrombocytopenia, transient decreases in platelet count</p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory insufficiency<sup>[Ref]</sup></p><p>One patient presented with respiratory insufficiency 12 days after receiving this drug.  The patient was found to have respiratory syncytial virus (RSV) and parainfluenza in respiratory secretions; episodes of hypotension were followed by seizures.  Approximately 30 days following the infusion, leukoencephalopathy was found and the patient died after withdrawal of life support, 52 days after this drug was infused.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Elevated cardiac troponin-I levels<sup>[Ref]</sup></p><p>Elevated cardiac troponin-I levels up to 0.176 mcg/L have been observed following infusion.  The clinical importance of this finding is unknown; however, cardiac toxicity has been observed in animal studies.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Vomiting</p><h3>Hepatic</h3><p>Elevated aminotransferases (ALT and/or AST) to greater than the upper limit of normal (ULN) occurred in 12 of 44 patients in clinical trials.  Two patients had AST and ALT elevations of up to 48 x ULN; these patients were otherwise asymptomatic with normal total bilirubin.  Following corticosteroid management, these abnormalities resolved.  One patient with preexisting transaminase elevations (who received this drug with the recommended corticosteroid regimen) became jaundiced about 7 weeks after the infusion.  Laboratory testing showed an AST level approximately 80 x ULN and ALT level approximately 45 x ULN.  Liver biopsy showed acute massive degeneration of hepatocytes, and massive mixed inflammatory infiltrate (primarily CD8-positive T-lymphocytes).  Following treatment with corticosteroids, the patient recovered to baseline.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated aminotransferases (27.3%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Zolgensma (10.1-10.5 kg) (onasemnogene abeparvovec)." AveXis, Bannockburn, IL. </p><h2>More about onasemnogene abeparvovec</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous uncategorized agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Onasemnogene abeparvovec-xioi Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Spinal Muscular Atrophy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>